We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.85B
AUM Growth
-$390M
Cap. Flow
-$60.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
29.91%
Holding
227
New
13
Increased
57
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$50.4M
2
FATE icon
Fate Therapeutics
FATE
+$49M
3
RVMD icon
Revolution Medicines
RVMD
+$46.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$43.8M
5
EPIX
ESSA Pharma
EPIX
+$40.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$301M
2
HALO icon
Halozyme
HALO
+$54.5M
3
CRL icon
Charles River Laboratories
CRL
+$47.7M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$34.2M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.84%
2 Industrials 0.82%
3 Technology 0.59%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRC
51
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$63.1M 0.64%
420,716
-253,162
-38% -$34.2M
OPCH icon
52
Option Care Health
OPCH
$3.4B
$63M 0.64%
2,595,814
+805,622
+45% +$18.7M
GBIO
53
DELISTED
Generation Bio
GBIO
$62M 0.63%
247,218
-600
-0.2% -$144K
EXEL icon
54
Exelixis
EXEL
$13.9B
$60.4M 0.61%
2,859,000
-73,000
-2% -$1.36M
OMCL icon
55
Omnicell
OMCL
$1.86B
$58.4M 0.59%
393,583
– –
GMED icon
56
Globus Medical
GMED
$10.4B
$55.9M 0.57%
729,420
– –
PEN icon
57
Penumbra
PEN
$12.5B
$54.8M 0.56%
205,692
+23,567
+13% +$6.33M
ESPR
58
DELISTED
Esperion Therapeutics
ESPR
$54.5M 0.55%
4,519,164
– –
BEAM icon
59
Beam Therapeutics
BEAM
$2.58B
$53.3M 0.54%
612,821
– –
VCRA
60
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$52.8M 0.54%
1,154,041
+501,209
+77% +$22.4M
SRPT icon
61
Sarepta Therapeutics
SRPT
$1.66B
$52.6M 0.53%
+569,168
New +$43.8M
VEEV icon
62
Veeva Systems
VEEV
$30.3B
$50.3M 0.51%
174,551
+1,904
+1% +$604K
TMO icon
63
Thermo Fisher Scientific
TMO
$211B
$49.6M 0.5%
86,879
+44,905
+107% +$24.6M
ABMD
64
DELISTED
Abiomed Inc
ABMD
$49.2M 0.5%
151,178
– –
IQV icon
65
IQVIA
IQV
$34.7B
$45.7M 0.46%
190,620
+13,220
+7% +$3.34M
MOH icon
66
Molina Healthcare
MOH
$10.3B
$45.6M 0.46%
168,255
-30,479
-15% -$8.05M
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$45.6M 0.46%
416,200
-1,500
-0.4% -$156K
ADPT icon
68
Adaptive Biotechnologies
ADPT
$3.56B
$45.4M 0.46%
1,336,023
+373,671
+39% +$13.5M
AMED
69
DELISTED
Amedisys
AMED
$45.1M 0.46%
302,798
+242,311
+401% +$50.4M
CI icon
70
Cigna
CI
$76.6B
$43.6M 0.44%
217,812
-38,930
-15% -$8.46M
SILK
71
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$43M 0.44%
781,660
-512,099
-40% -$26.8M
MDT icon
72
Medtronic
MDT
$107B
$42.5M 0.43%
339,125
-20,500
-6% -$2.65M
GH icon
73
Guardant Health
GH
$19.5B
$42.5M 0.43%
339,894
-39,715
-10% -$4.72M
PACB icon
74
Pacific Biosciences
PACB
$422M
$42M 0.43%
1,643,159
– –
ZBH icon
75
Zimmer Biomet
ZBH
$17.7B
$41M 0.42%
288,484
– –
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2021 Portfolio in Review

As of Q3 2021, Bellevue Group held 227 positions worth $9.85B, down 3.8% from $10.2B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q3 2021 filing shows 13 new, 57 increased, 57 reduced and 7 closed positions. Its largest new stake was Sarepta Therapeutics: 569,168 shares worth $52.6M. The largest sale was Moderna, an estimated $301M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2021 buy was Sarepta Therapeutics: 569,168 shares worth $52.6M.
  • Bellevue Group added most to Amedisys in Q3 2021, an estimated $50.4M increase.
  • Bellevue Group's biggest Q3 2021 reduction was Moderna, cutting an estimated $301M.
  • Bellevue Group fully exited Eargo, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.85B portfolio in Q3 2021.
  • Bellevue Group opened 13 new positions and closed 7 in Q3 2021.
  • Bellevue Group's portfolio value fell 3.8% quarter-over-quarter to $9.85B.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.